Neurocognitive effects of agomelatine treatment in schizophrenia patients suffering from comorbid depression: results from the AGOPSYCH study
AbstractBackgroundCognitive impairment in schizophrenia is highly disabling and remains one of the major therapeutic challenges. Agomelatine (AGO), an agonist at melatonergic MT1/MT2 receptors and antagonist at 5-HT2C receptors, increases dopamine and norepinephrine in the prefrontal cortex and may
Gespeichert in:
| Hauptverfasser: | , , |
|---|---|
| Dokumenttyp: | Article (Journal) |
| Sprache: | Englisch |
| Veröffentlicht: |
August 2018
|
| In: |
Journal of clinical psychopharmacology
Year: 2018, Jahrgang: 38, Heft: 4, Pages: 357-361 |
| ISSN: | 1533-712X |
| DOI: | 10.1097/JCP.0000000000000909 |
| Online-Zugang: | Verlag, Volltext: https://doi.org/10.1097/JCP.0000000000000909 Verlag: insights.ovid.com 
|
| Verfasserangaben: | Susanne Englisch, Hanna Jung, Sarah Eisenacher, Antje Lewien, Anna Becker, Ulrike Nowak, Hanna Braun, Jascha Thiem, Andreas Meyer-Lindenberg and Mathias Zink |
MARC
| LEADER | 00000caa a2200000 c 4500 | ||
|---|---|---|---|
| 001 | 1688922547 | ||
| 003 | DE-627 | ||
| 005 | 20220817220251.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 200130s2018 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1097/JCP.0000000000000909 |2 doi | |
| 035 | |a (DE-627)1688922547 | ||
| 035 | |a (DE-599)KXP1688922547 | ||
| 035 | |a (OCoLC)1341300271 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 084 | |a 33 |2 sdnb | ||
| 100 | 1 | |a Englisch, Susanne Angelika |d 1976- |e VerfasserIn |0 (DE-588)138966184 |0 (DE-627)70316645X |0 (DE-576)309056950 |4 aut | |
| 245 | 1 | 0 | |a Neurocognitive effects of agomelatine treatment in schizophrenia patients suffering from comorbid depression |b results from the AGOPSYCH study |c Susanne Englisch, Hanna Jung, Sarah Eisenacher, Antje Lewien, Anna Becker, Ulrike Nowak, Hanna Braun, Jascha Thiem, Andreas Meyer-Lindenberg and Mathias Zink |
| 264 | 1 | |c August 2018 | |
| 300 | |a 5 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Gesehen am 30.01.2020 | ||
| 520 | |a AbstractBackgroundCognitive impairment in schizophrenia is highly disabling and remains one of the major therapeutic challenges. Agomelatine (AGO), an agonist at melatonergic MT1/MT2 receptors and antagonist at 5-HT2C receptors, increases dopamine and norepinephrine in the prefrontal cortex and may | ||
| 700 | 1 | |a Meyer-Lindenberg, Andreas |d 1965- |e VerfasserIn |0 (DE-588)1029137390 |0 (DE-627)732483069 |0 (DE-576)376589876 |4 aut | |
| 700 | 1 | |a Zink, Mathias |d 1968- |e VerfasserIn |0 (DE-588)121715221 |0 (DE-627)705627217 |0 (DE-576)292845715 |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Journal of clinical psychopharmacology |d Hagerstown, Md. : Lippincott Williams & Wilkins, 1981 |g 38(2018), 4, Seite 357-361 |h Online-Ressource |w (DE-627)33428998X |w (DE-600)2057059-4 |w (DE-576)098000314 |x 1533-712X |7 nnas |a Neurocognitive effects of agomelatine treatment in schizophrenia patients suffering from comorbid depression results from the AGOPSYCH study |
| 773 | 1 | 8 | |g volume:38 |g year:2018 |g number:4 |g pages:357-361 |g extent:5 |a Neurocognitive effects of agomelatine treatment in schizophrenia patients suffering from comorbid depression results from the AGOPSYCH study |
| 856 | 4 | 0 | |u https://doi.org/10.1097/JCP.0000000000000909 |x Verlag |x Resolving-System |3 Volltext |
| 856 | 4 | 0 | |u insights.ovid.com |x Verlag |
| 951 | |a AR | ||
| 992 | |a 20200130 | ||
| 993 | |a Article | ||
| 994 | |a 2018 | ||
| 998 | |g 121715221 |a Zink, Mathias |m 121715221:Zink, Mathias |d 60000 |e 60000PZ121715221 |k 0/60000/ |p 10 |y j | ||
| 998 | |g 1029137390 |a Meyer-Lindenberg, Andreas |m 1029137390:Meyer-Lindenberg, Andreas |d 60000 |e 60000PM1029137390 |k 0/60000/ |p 9 | ||
| 999 | |a KXP-PPN1688922547 |e 358340680X | ||
| BIB | |a Y | ||
| SER | |a journal | ||
| JSO | |a {"physDesc":[{"extent":"5 S."}],"recId":"1688922547","origin":[{"dateIssuedDisp":"August 2018","dateIssuedKey":"2018"}],"person":[{"display":"Englisch, Susanne Angelika","family":"Englisch","given":"Susanne Angelika","role":"aut"},{"display":"Meyer-Lindenberg, Andreas","given":"Andreas","role":"aut","family":"Meyer-Lindenberg"},{"display":"Zink, Mathias","role":"aut","given":"Mathias","family":"Zink"}],"relHost":[{"note":["Gesehen am 21.06.2019"],"language":["eng"],"type":{"media":"Online-Ressource","bibl":"periodical"},"part":{"volume":"38","year":"2018","issue":"4","text":"38(2018), 4, Seite 357-361","extent":"5","pages":"357-361"},"title":[{"title":"Journal of clinical psychopharmacology","title_sort":"Journal of clinical psychopharmacology"}],"id":{"zdb":["2057059-4"],"issn":["1533-712X"],"eki":["33428998X"]},"pubHistory":["1.1981 -"],"origin":[{"dateIssuedDisp":"1981-","dateIssuedKey":"1981","publisherPlace":"Hagerstown, Md. ; [Erscheinungsort nicht ermittelbar]","publisher":"Lippincott Williams & Wilkins ; Ovid"}],"disp":"Neurocognitive effects of agomelatine treatment in schizophrenia patients suffering from comorbid depression results from the AGOPSYCH studyJournal of clinical psychopharmacology","physDesc":[{"extent":"Online-Ressource"}],"recId":"33428998X"}],"type":{"bibl":"article-journal","media":"Online-Ressource"},"language":["eng"],"note":["Gesehen am 30.01.2020"],"title":[{"subtitle":"results from the AGOPSYCH study","title":"Neurocognitive effects of agomelatine treatment in schizophrenia patients suffering from comorbid depression","title_sort":"Neurocognitive effects of agomelatine treatment in schizophrenia patients suffering from comorbid depression"}],"name":{"displayForm":["Susanne Englisch, Hanna Jung, Sarah Eisenacher, Antje Lewien, Anna Becker, Ulrike Nowak, Hanna Braun, Jascha Thiem, Andreas Meyer-Lindenberg and Mathias Zink"]},"id":{"eki":["1688922547"],"doi":["10.1097/JCP.0000000000000909"]}} | ||
| SRT | |a ENGLISCHSUNEUROCOGNI2018 | ||